Emerging benefits of Fc fusion technology in the context of recombinant factor VIII replacement therapy.

ABSTRACT: Although the primary reason for recombinant factor VIII Fc fusion protein (rFVIIIFc) development was to reduce treatment burden associated with routine prophylaxis, new evidence suggests additional benefits of Fc fusion technology in the treatment of people with haemophilia A. Preclinical research has been utilized to characterize the potential immunomodulatory properties of rFVIIIFc, including an ability to reduce inflammation and induce tolerance to factor VIII. This has since been expanded into clinical research in immune tolerance induction (ITI) with rFVIIIFc, results of which suggest the potential for rapid tolerization in first-time ITI patients and therapeutic benefit in patients undergoing rescue ITI. The potential for improved joint health through the anti-inflammatory properties

SUBMITTER: Meeks SL 

PROVIDER: S-EPMC7818509 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature